These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27553973)

  • 1. Why is viral eradication so important in patients with HCV-related cirrhosis?
    Velosa J
    Antivir Ther; 2017; 22(1):1-12. PubMed ID: 27553973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion of disease manifestations after HCV eradication.
    van der Meer AJ; Berenguer M
    J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
    Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
    Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
    Spârchez Z; Mocan T
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis.
    Toshikuni N
    Gut Liver; 2017 May; 11(3):335-348. PubMed ID: 27840363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Elimination of HCV-Related Liver Disease.
    Pradat P; Virlogeux V; Trépo E
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30301201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic benefits of HCV cure.
    Calvaruso V; Craxì A
    J Hepatol; 2020 Dec; 73(6):1548-1556. PubMed ID: 32777323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
    Gentile I; Scotto R; Coppola C; Staiano L; Amoruso DC; De Simone T; Portunato F; De Pascalis S; Martini S; Macera M; Viceconte G; Tosone G; Buonomo AR; Borgia G; Coppola N
    Hepatol Int; 2019 Jan; 13(1):66-74. PubMed ID: 30523552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
    Floreani A; Baldo V; Rizzotto ER; Carderi I; Baldovin T; Minola E
    J Clin Gastroenterol; 2008 Jul; 42(6):734-7. PubMed ID: 18285717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
    Fehily SR; Papaluca T; Thompson AJ
    Semin Liver Dis; 2019 Jul; 39(3):341-353. PubMed ID: 31041785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
    Gonzalez HC; Gordon SC
    Gastroenterol Clin North Am; 2020 Jun; 49(2):301-314. PubMed ID: 32389364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
    Cholongitas E; Pipili C; Papatheodoridis G
    World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.